Parsons Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $747K | Buy |
5,911
+115
| +2% | +$15.2K | 0.03% | 321 |
|
|
2026
Q1 | $808K | Sell |
5,796
-49
| -0.8% | -$6.86K | 0.04% | 301 |
|
|
2025
Q4 | $717K | Buy |
+5,845
| New | +$710K | 0.04% | 285 |
|
|
2023
Q3 | – | Sell |
-4,768
| Closed | -$367K | – | 423 |
|
|
2023
Q2 | $367K | Sell |
4,768
-399
| -8% | -$31.8K | 0.03% | 340 |
|
|
2023
Q1 | $429K | Buy |
5,167
+1
| +0% | +$83 | 0.03% | 315 |
|
|
2022
Q4 | $444K | Sell |
5,166
-17
| -0.3% | -$1.35K | 0.04% | 299 |
|
|
2022
Q3 | $320K | Hold |
5,183
| – | – | 0.03% | 338 |
|
|
2022
Q2 | $320K | Sell |
5,183
-92
| -2% | -$5.7K | 0.03% | 341 |
|
|
2022
Q1 | $314K | Buy |
5,275
+75
| +1% | +$4.79K | 0.02% | 362 |
|
|
2021
Q4 | $378K | Buy |
5,200
+56
| +1% | +$3.86K | 0.03% | 345 |
|
|
2021
Q3 | $359K | Sell |
5,144
-148
| -3% | -$10.4K | 0.03% | 338 |
|
|
2021
Q2 | $364K | Sell |
5,292
-150
| -3% | -$10K | 0.03% | 336 |
|
|
2021
Q1 | $352K | Sell |
5,442
-346
| -6% | -$22.3K | 0.03% | 322 |
|
|
2020
Q4 | $337K | Sell |
5,788
-2,293
| -28% | -$138K | 0.03% | 309 |
|
|
2020
Q3 | $511K | Buy |
8,081
+215
| +3% | +$14.9K | 0.05% | 242 |
|
|
2020
Q2 | $605K | Buy |
7,866
+538
| +7% | +$41.2K | 0.06% | 217 |
|
|
2020
Q1 | $548K | Sell |
7,328
-660
| -8% | -$45.6K | 0.07% | 210 |
|
|
2019
Q4 | $519K | Sell |
7,988
-300
| -4% | -$19.5K | 0.05% | 242 |
|
|
2019
Q3 | $525K | Sell |
8,288
-2,760
| -25% | -$180K | 0.06% | 237 |
|
|
2019
Q2 | $746K | Sell |
11,048
-145
| -1% | -$9.54K | 0.08% | 208 |
|
|
2019
Q1 | $728K | Sell |
11,193
-430
| -4% | -$28.6K | 0.08% | 206 |
|
|
2018
Q4 | $727K | Sell |
11,623
-235
| -2% | -$16.4K | 0.09% | 194 |
|
|
2018
Q3 | $916K | Buy |
11,858
+34
| +0.3% | +$2.57K | 0.1% | 188 |
|
|
2018
Q2 | $838K | Buy |
11,824
+9
| +0.1% | +$636 | 0.09% | 198 |
|
|
2018
Q1 | $891K | Sell |
11,815
-550
| -4% | -$43.7K | 0.1% | 187 |
|
|
2017
Q4 | $886K | Sell |
12,365
-250
| -2% | -$19K | 0.1% | 188 |
|
|
2017
Q3 | $1.02M | Buy |
12,615
+305
| +2% | +$23.3K | 0.12% | 169 |
|
|
2017
Q2 | $871K | Hold |
12,310
| – | – | 0.11% | 186 |
|
|
2017
Q1 | $836K | Buy |
12,310
+190
| +2% | +$13.4K | 0.11% | 180 |
|
|
2016
Q4 | $868K | Buy |
12,120
+730
| +6% | +$54.3K | 0.12% | 171 |
|
|
2016
Q3 | $901K | Buy |
11,390
+300
| +3% | +$24.4K | 0.12% | 167 |
|
|
2016
Q2 | $925K | Sell |
11,090
-7,325
| -40% | -$650K | 0.13% | 168 |
|
|
2016
Q1 | $1.69M | Sell |
18,415
-98
| -0.5% | -$8.84K | 0.23% | 114 |
|
|
2015
Q4 | $1.87M | Sell |
18,513
-7,100
| -28% | -$739K | 0.26% | 103 |
|
|
2015
Q3 | $2.52M | Sell |
25,613
-2,890
| -10% | -$321K | 0.37% | 71 |
|
|
2015
Q2 | $3.34M | Buy |
28,503
+50
| +0.2% | +$5.46K | 0.44% | 59 |
|
|
2015
Q1 | $2.79M | Buy |
28,453
+300
| +1% | +$30.5K | 0.39% | 63 |
|
|
2014
Q4 | $2.65M | Sell |
28,153
-820
| -3% | -$84.8K | 0.35% | 78 |
|
|
2014
Q3 | $3.08M | Sell |
28,973
-1,075
| -4% | -$105K | 0.43% | 62 |
|
|
2014
Q2 | $2.49M | Sell |
30,048
-248
| -0.8% | -$19.3K | 0.34% | 79 |
|
|
2014
Q1 | $2.15M | Sell |
30,296
-1,852
| -6% | -$145K | 0.31% | 85 |
|
|
2013
Q4 | $2.41M | Buy |
32,148
+4,208
| +15% | +$293K | 0.36% | 75 |
|
|
2013
Q3 | $1.76M | Buy |
27,940
+5,940
| +27% | +$355K | 0.29% | 106 |
|
|
2013
Q2 | $1.13M | Buy |
+22,000
| New | +$1.15M | 0.19% | 136 |
|
Other funds holding GILD
Parsons Capital Management's GILD Position: Q2 2026 in Review
Parsons Capital Management increased its Gilead Sciences (GILD) stake by 2% in Q2 2026, buying an estimated $15.2K and bringing the position to 5,911 shares worth $747K. The position accounts for 0.03% of the portfolio, ranked #321.
Parsons Capital Management first reported a position in GILD in Q2 2013 and has held it in 44 quarters since. The position peaked at $3.34M in Q2 2015. 1,412 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Parsons Capital Management held 5,911 shares of Gilead Sciences worth $747K as of Q2 2026.
- Parsons Capital Management bought 115 Gilead Sciences shares in Q2 2026, an estimated $15.2K.
- Gilead Sciences made up 0.03% of Parsons Capital Management's portfolio in Q2 2026, its #321 holding.
- Parsons Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 44 quarters since.
- Parsons Capital Management's Gilead Sciences position peaked at $3.34M in Q2 2015.
- 1,412 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Parsons Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.